Estrella Immunopharma (Estrella Immunopharma) EBIT : $-3.36 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma EBIT?

Estrella Immunopharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-0.47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.36 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Estrella Immunopharma's annualized ROC % for the quarter that ended in Mar. 2024 was -99.73%. Estrella Immunopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -111.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Estrella Immunopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -30.94%.

Estrella Immunopharma EBIT Historical Data

The historical data trend for Estrella Immunopharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma EBIT Chart

Estrella Immunopharma Annual Data

Trend

Jun21

EBIT

-0.73

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial					-2.76	-2.74	-1.87	-1.02	-0.47

Competitive Comparison of Estrella Immunopharma's EBIT

For the Biotechnology subindustry, Estrella Immunopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Estrella Immunopharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's EV-to-EBIT falls into.

Estrella Immunopharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.36 Mil.

Estrella Immunopharma (NAS:ESLA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Estrella Immunopharma's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-1.88 * ( 1 - 0% )	/	( (0.0019999999999989	+	3.768)	/ 2 )
=	-1.88	/	1.885
=	-99.73 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.447	-	0.399	-	( 9.046	-	max(0, 0.399	-	9.447	+	9.046	))
=	0.0019999999999989

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.633	-	0.138	-	( 4.727	-	max(0, 0.138	-	8.633	+	4.727	))
=	3.768

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Estrella Immunopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.88	/	( ( (0 + max(0.0019999999999998, 0))	+	(0 + max(3.362, 0)) )	/	2 )
=	-1.88	/	( ( 0.0019999999999998	+	3.362 )	/	2 )
=	-1.88	/	1.682
=	-111.77 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.401)	-	(0.399	+	0	+	0)
=	0.0019999999999998

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.5)	-	(0.138	+	0	+	0)
=	3.362

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Estrella Immunopharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-3.361	/	10.864
	=	-30.94 %

Estrella Immunopharma EBIT Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines